摘要
目的比较阿立哌唑与奎硫平治疗女性首发精神分裂症的疗效和安全性。方法采用随机、双盲、双模拟平行对照的方法,对符合中国精神障碍分类与诊断标准第3版(CCMD-3)精神分裂症诊断标准的女性首发精神分裂症患者,随机使用阿立哌唑(50例)和奎硫平(51例)治疗8周。采用阳性症状与阴性症状量表(PANSS)、临床总体印象量表(CGI)评定疗效,采用副反应量表(TESS)评定副反应。结果治疗8周后,阿立哌唑组痊愈率为38．0％,显效率为66．0％;奎硫平组痊愈率为35．3％,显效率为66．7％。阿立哌唑组总不良反应发生率为33．3％,奎硫平组总不良反应发生率为35．2％。结果显示,两组在疗效和不良反应发生率方面均无显著性差异(P>0．05)。阿立哌唑组和奎硫平组均出现较多的不良反应是嗜睡(14．8％vs19．6％)、头昏和昏厥(11．1％vs12．9％);阿立哌唑组恶心呕吐、头痛的发生率比奎硫平组多(12．9％vs1．9％,P<0．05;16．7％vs1．9%,P<0．01),奎硫平组口干、食欲减退或厌食比阿立哌唑组多(均为14．8％vs1．9％,P<0．05)。两组锥体外系反应均不明显,较少引起体重增加和月经紊乱,没有发现溢乳现象。结论阿立哌唑和奎硫平对女性首发精神分裂症疗效相当,不良反应轻,且表现有异有同。两种药物均为疗效好、安全性高、对体重和月经影响较小、无溢乳的抗精神病药,有利于提高女性精神分裂症患者服药的依从性。
Objective To compare the efficacy and the safety of Aripiprazole and Quetiapine in the treatment of female first-episode schizophrenia. Methods The randomized, double blind, double dummy parallel controlled was designed for this study. All of the cases were diagnosed as schizophrenia in accordance with the CCMD-3 diagnosis standard and randomized into two groups which were treated with Aripiprazole or Quetiapine for 8 weeks. The Positive and Negative Syndrome Scale（ PANSS）, Clinical Global Impression（CGI） and Treatment Emergent Side effect Scale （TESS） were used to evaluate the efficacy and adverse effects respectively before and at the ends of 2,4,8 weeks treatment. Results 101 adult female first-episode schizophrenic patients were recruited in this study. The remission rates of aripiprazole was 38.0% and the significant efficacy rate was 66. 0% after 8 weeks while that was 35.3% and 66. 7% in Quetiapine group. There was no significant difference between the two groups （ P 〉0. 05 ）. The incidence rate of adverse effect was 33.3% in Aripiprazole group and that was 35. 2% in Quetiapine group, without any significant difference between them（ P 〉0. 05 ）. The adverse effect either in Afipiprazole group or in Quetiapine group was drowsiness（ 14.8% vs 19.6% ）, dizziness and faint （ 11.1% vs 12. 9% ）. There was no significant difference between the two groups （P 〉0.05）. The rate of nausea and vomiting, headache in Aripiprazole group was higher than that in Quetiapine group （ 12. 9% vs 1.9%, P 〈 0.05 ; 16. 7% vs 1.9% ,P 〈0. 01 ）. The rate of dry mouth ,decrease of appetite or anorexia in quetiapine group was higher than that in aripiprazole group（ 14. 8% vs 1.9%, P 〈 0. 05 ; 14. 8% vs 1.9% , P 〈 0. 05 ）. Both drugs showed low extrapyramidal symptoms, less endocrine change, less weight gain and have not found amenorrhea galactorrhea syndrome during treatment. Conclusions The results suggested that aripiprazole was as effective as Quetiapine for the treatment of female first-episode schizophrenic and fewer side effects in them. Although two drugs had different or the same side effects profile, both were effictive and safe antipsychotic drugs in the treatment of female first-episode sihizophrenic. They were beneficial to improve the therapeutic compliance of female first-episode schizophrenic patients.
出处
《中国神经精神疾病杂志》
CAS
CSCD
北大核心
2006年第6期511-517,共7页
Chinese Journal of Nervous and Mental Diseases
关键词
阿立哌唑
奎硫平
女性
首发精神分裂症
对照研究
Aripiprazole Quetiapine Female First-episode schizophrenia Controlled study
